Recent evidence highlight long non-coding RNAs (lncRNAs) as crucial regulators of cancer biology, which contribute to essential cancer cell functions such as cell proliferation, apoptosis and metastasis. In non small cell lung cancer (NSCLC), several lncRNAs expression are misregulated and have been nominated as critical actors in NSCLC tumorigenesis. LncRNA ANRIL was firstly found to be required for the PRC2 recruitment to and silencing of p15
Introduction
Lung cancer is the most common type of cancer and the primary cause of cancer death worldwide (1) . NSCLC accounts for 80% of all lung cancer cases, represents the most prevalent class of this cancer type and includes several histological subtypes such as squamous cell carcinoma (SCC), adenocarcinoma and large cell carcinoma (LCC) (2, 3) . In spite of current advances in the treatments for NSCLC, including surgical therapy, chemotherapy and molecular targeting therapy, the overall 5-year survival rate for NSCLC patients have not been markedly improved over years and remains as low as 15% (4) .
Therefore, a greater understanding of the molecular mechanisms involved in the development, progression and spread of the NSCLC is essential for the developing of specific diagnostic methods and designing of more individualized and effective therapeutic strategies.
Recently, studies using the great advances in genomic technologies have revealed the majority of the human genome is transcribed, whereas only 2% of the transcribed genome codes for protein (5) . Meanwhile, it is becoming increasingly apparent that the large majority of genome is transcribed into non-coding RNAs (ncRNAs) including microRNAs and long non-coding RNAs (lncRNAs) (6) . The ENCODE Consortium has elucidated the prevalence of thousands of human lncRNAs, but only very few of them have been assigned with any biological function (7) . To date, studies showed that miRNAs play important roles in the post-transcriptional regulation of gene expression; however, the lncRNAs counterpart of ncRNA is not well characterized (8) including modulation of apoptosis and invasion, reprogramming stem cell pluripotency, and parental imprinting through the regulation of gene expression by chromatin remodeling, histone protein modification, regulation of mRNA splicing and acting as sponges for microRNAs (9) (10) (11) (12) .
In the past decade, lots of evidence have linked the dysregulation of lncRNAs with diverse human diseases, in particular cancers (13) (14) (15) . Therefore, identification of cancer-associated lncRNAs and investigation of their molecular and biological functions are important in understanding the molecular biology of NSCLC development and progression. Our previous study showed that lncRNA ANRIL was significantly up-regulated in gastric cancer, and increased ANRIL promoted gastric cancer cells proliferation and inhibited apoptosis by epigenetic silencing of miR-99a and miR-449a transcription (16) . Moreover, ANRIL can bind to and recruits PRC2 to repress the expression of p15INK4B locus, which resulted in increased cell proliferation (17, 18) .
However, the ANRIL clinical significance and potential role in NSCLC development and progression is still not documented.
In this study, we found that lncRNA ANRIL expression was increased in NSCLC tissues compared with adjacent normal tissues. Its expression level was significantly correlated with TNM stages and tumor size. Moreover, patients with higher level of ANRIL expression had a relatively poor prognosis. Furthermore, we investigated the effects of ANRIL expression on NSCLC cell phenotype in vitro and in vivo with loss of function study.
Moreover, we also showed that ANRIL could bind to PRC2 to repress KLF2 and P21 that ANRIL affected NSCLC cells proliferation and apoptosis partly via silencing of KLF2 and P21 transcription. This study advances our understanding of the role of lncRNAs, such as a regulator of pathogenesis of NSCLC and facilitates the development of lncRNA-directed diagnostics and therapeutics.
Materials and Methods

Tissue collection
We obtained 68 paired NSCLC and adjacent non-tumor lung tissues from patients who underwent surgery at Jiangsu Province Hospital between 2010 and 2011, and were diagnosed with NSCLC based on histopathological evaluation. Clinicopathological characteristics, including tumor-node-metastasis (TNM) staging, were recorded. No local or systemic treatment was conducted in these patients before surgery. All collected tissue samples were immediately snap-frozen in liquid nitrogen and stored at -80°C until required. Our study was approved by the Research Ethics Committee of Nanjing Medical University, China. Written informed consent was obtained from all patients.
Cell lines
Five NSCLC adenocarcinoma cell lines (PC9, SPC-A1, NCI-H1975, H1299, and H358), and one NSCLC squamous carcinomas cell lines (H520) were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). A549, H1975, H1299 and H520 cells were cultured in RPMI 1640; 16HBE, PC9
and SPC-A1 cells were cultured in DMEM (GIBCO-BRL) medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) at 37ºC/5% CO 2 . All cell lines were authenticated by short tandem repeat DNA profiling.
RNA extraction and qPCR assays
Total RNA was isolated with Trizol reagent (Invitrogen) according to the manufacturer's instructions. Total RNA (500 ng) was reverse transcribed in a final volume of 10 µl using random primers under standard conditions for the PrimeScript RT reagent Kit (TaKaRa, Dalian, China). We used the SYBR Premix Ex Taq (TaKaRa, Dalian, China) to determine ANRIL expression levels, following the manufacturer's instructions. Results were normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The specific primers used are shown in Supplementary table S1. The qPCR assays were conducted on an ABI 7500, and data collected with this instrument. Our qPCR results were analyzed and expressed relative to threshold cycle (CT) values, and then converted to fold changes.
Cell transfection
Human ANRIL cDNA clone L6ChoCKO-2-E10 with functional region was provided by 
Cell viability assays
Cell viability was monitored using a Cell Proliferation Reagent Kit I (MTT) (Roche Applied Science). The SPC-A1, H1299, PC9 or A549 cells transfected with si-ANRIL (3000 cells/well) were grown in 96-well plates. Cell viability was assessed every 24 h following the manufacturer's protocol. All experiments were performed in quadruplicate.
For each treatment group wells were assessed in triplicate. 
RNA immunoprecipitation
For immunoprecipitation (IP) of endogenous PRC2 complexes from whole-cell extracts, cells were lysed. The supernatants were incubated with protein A Sepharose beads coated with antibodies that recognized EZH2, SNRNP70 or with control IgG (millipore) for 6hr at 4℃. After the beads were washed with wash buffer, the complexes were incubated with 0.1% SDS/0.5 mg/ml Proteinase K (30 min at 55℃) to remove proteins, respectively.
The PRC2 isolated from the IP materials was further assessed by qPCR analysis (19) .
Chromatin Immunoprecipitation
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Western blot assay and antibodies
Cells protein lysates were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to 0.22μm NC membranes （Sigma） and incubated with specific antibodies. ECL chromogenic substrate was used to were quantified by densitometry (Quantity One software; Bio-Rad). GAPDH antibody was used as control, Anti-P21, CDK2, CDK4, CDK6, P15 and PARP (1:1000) were purchased from Cell Signaling Technology, Inc (CST); Anti-KLF2 were purchased from sigma.
Statistical analysis
All statistical analyses were performed using SPSS 17.0 software (IBM, Chicago, IL, USA).
The significance of differences between groups was estimated by the Student t-test, Wilcoxon test or χ2 test. DFS and OS rates were calculated by the Kaplan-Meier method with the log-rank test applied for comparison. The date of survival were evaluated by univariate and multivariate Cox proportional hazards models. Variables with p < 0.05 in univariate analysis were used in subsequent multivariate analysis on the basis of Cox regression analyses. Kendall's Tau-b and Pearson correlation analyses were used to investigate the correlation between ANRIL and KLF2 expressions. Two-sided p-values were calculated, and a probability level of 0.05 was chosen for statistical significance. ANRIL expression levels were investigated in 68 paired NSCLC samples and adjacent histologically normal tissues using qPCR assays. ANRIL expression was significantly up-regulated (Fold change >1.5, P < 0.01) in 76% (52/68) of cancerous tissues compared with normal tissues (Fig.1A) ; the ANRIL expression level in each patient was shown in Supplementary table S2. Increased ANRIL expression levels in NSCLC were significantly correlated with tumor size (p = 0.001), and advanced pathological stage (p=0.007). However, ANRIL expression was not associated with other parameters such as gender (p = 0.625) and age (p = 0.627) in NSCLC (Table1).
To investigate whether up-regulation of ANRIL is caused by DNA copy number variation, we referred to array comparative genomic hybridization (aCGH) database in GSE20393, where deposits 52 lung cancer copy number alteration data generated by Agilent Human Genome CGH 244A Microarrays. We investigated 26 probes representing region of ANRIL and extracted GLAD segmented copy number of these probes. The results showed that there is no significant gain of DNA copy number in this region, suggesting that up-regulation of ANRIL in lung cancer is not due to copy number variation ( Supplementary Fig. S1A ).
Association of ANRIL expression with patients survival
Kaplan-Meier survival analysis was conducted to investigate the correlation between ANRIL expression and NSCLC patient prognosis. According to relative ANRIL expression in tumor tissues, the 68 NSCLC patients were classified into two groups: the high ANRIL 
group (n = 34, fold-change ≤ mean ratio); and the low ANRIL group (n = 34, fold-change ≥mean ratio) (Fig. 1B) . With respect to progression-free survival (PFS), this was 35.3% for the high ANRIL group, and 13.6% for the low ANRIL group. Median survival time for the high ANRIL group was 31 months, and 14 months for the low ANRIL group (Fig. 1C) .
The overall survival rate over 3 years for the high ANRIL group was 44.4%, and 20.8% for the low ANRIL group. Median survival time for the high ANRIL group was 32 months, and 18 months for the low ANRIL group (Fig. 1D ).
Univariate analysis identified three prognostic factors: lymph node metastasis; TNM stage; and ANRIL expression level. Other clinicopathological features such as gender and age were not statistically significant prognosis factors (Supplementary Table S3 ).
Multivariate analysis of the three prognosis factors confirmed that HR for ARAIL expression is 3.509 (95%CI: 1.619-7.607) of progression-free survival, indicating that ANRIL expression may serve as a potential independent prognostic value in NSCLC (Supplementary Table S4 ).
Modulation of ANRIL expression in NSCLC cells
We next performed qPCR analysis to examine the expression of ANRIL in 6 human NSCLC cell lines, including both adenocarcinoma and squamous carcinoma subtypes ( Fig. 2A) . To investigate the functional effects of ANRIL in NSCLC cells, we modulated its expression through RNA interference. QPCR analysis of ANRIL levels was performed 48 h post-transfection. ANRIL expression was knocked down by 74% in SPC-A1 cells, 75%
in H1299 cells and 94% in PC9 cells by si-ANRIL transfection when compared with control cells (si-NC) (Fig. 2B) .
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Knockdown of ANRIL impaired NSCLC cells proliferation and induced apoptosis
To assess the role of ANRIL in NSCLC, we investigated the effect of targeted knockdown of ANRIL on cell proliferation. MTT assays revealed that cell growth was inhibited in SPC-A1, H1299 and PC9 cells transient transfected with si-ANRIL compared with controls (Fig. 2C) . Meanwhile, knockdown of ANRIL expression could also inhibit A549 cells (with relative low endogenous ANRIL expression level) proliferation (Supplementary Fig. S1B ). Colony formation assay results revealed that clonogenic survival was inhibited following down-regulation of ANRIL in SPC-A1, H1299 and PC9cells (Fig. 2D) . However, over-expression of ANRIL in 16HBE cells showed no significant effect on cell proliferation (Supplementary Fig. S1C ).
To further examine whether the effect of knockdown ANRIL on proliferation of NSCLC cells reflected cell cycle arrest, cell cycle progression was analyzed by flow cytometry analysis. The results revealed that SPC-A1 and PC9 cells transfected with si-ANRIL had an obvious cell cycle arrest at the G1/G0 phase and had a decreased G2/S phase (Fig. 3A) . To determine whether NSCLC cell proliferation was influenced by cell apoptosis, we performed flow cytometry and Tunel staining analysis. The results showed that NSCLC cells transfected with ANRIL siRNA promoted apoptosis in comparison with that in control cells (Fig. 3B and 2C ). These data indicate that ANRIL could promote the proliferation phenotype of NSCLC cells.
Decreased ANRIL expression inhibits NSCLC cells migration
To investigate the effect of ANRIL knockdown on NSCLC cells migration, transwells assays were performed. The results showed that decreased ANRIL expression levels Fig. S1D ).
Down-regulation of ANRIL inhibits NSCLC cells tumorigenesis in vivo.
To explore whether the level of ANRIL expression could affect tumorigenesis, PC9 cells stably transfected with sh-ANRIL or empty vector were inoculated into female nude mice.
Eighteen days after the injection, the tumors formed in the sh-ANRIL group were substantially smaller than those in the control group (Fig. 4A) . Moreover, the mean tumor weight at the end of the experiment was markedly lower in the sh-ANRIL group (0.62 ± 0.35 g) compared with the empty vector group (1.41± 0.57 g) (Fig. 4B ). QPCR analysis found that the levels of ANRIL expression in tumor tissues formed from sh-ANRIL cells were lower than in tumors formed in the control group (Fig. 4C) . Tumors formed from sh-ANRIL-transfected PC9 cells exhibited decreased positive for Ki67 than those from control cells (Fig. 4D) . These findings indicate that knockdown of ANRIL inhibits tumor growth in vivo.
ANRIL silences KLF2 and P21 transcription by binding with EZH2
Previously studies have indicated that ANRIL could silence p15 INK4 transcription and contribute to cancer cells proliferation (18) . The results of qPCR showed that p15 and p16 expression was increased in SPCA1 and H1299 cells with transfection of si-ANRIL;
however, there was no significant difference of p15 expression in PC9 cells when knockdown of ANRIL expression ( Fig. 5A and Supplementary Fig. S1E ). There are evidence showed that EZH2 could regulate KLF2 and P21 expression (20, 21) , and our qPCR results also showed that inhibition of ANRIL expression led to increased KLF2 and P21 expression. Moreover, knockdown of EZH2 or SUZ12 could also up-regulate KLF2 and P21 expression (Fig. 5B) . Meanwhile, the western blot assays showed the same results (Fig. 5C) , which indicated that KLF2 and P21 could be ANRIL novel targets in PC9 cells. Additionally, we found that ANRIL RNAs were mostly located in the nucleus (Fig.   5D ).
To further investigate whether ANRIL repress KLF2 and P21 expression through binding PRC2, we performed RIP analysis and the results showed that ANRIL could directly bind with EZH2 in PC9 cells (Fig. 6A) . Furthermore, the results of ChIP assays showed that EZH2 could directly bind to KLF2 and P21 promoter region and mediate H3K27me3 modification (Fig. 6B) . However, knockdown of ANRIL reduced EZH2 binding with KLF2 and P21 promoter (Fig. 6C) . Finally, we detected the KLF2 expression in NSCLC tissues, and found that there is an inverse relationship between ANRIL and KLF2 expression (Fig. 6D) . These data suggested that ANRIL promotes NSCLC PC9 cells proliferation is not dependent on regulation p15 expression, but also through silencing of KLF2 and P21 transcription.
Silence of KLF2 is potentially involved in the oncogenic function of ANRIL.
To investigate whether KLF2 is involved in the ANRIL-induced increase in NSCLC cell proliferation, we performed gain of function assays. The results of western blot showed that KLF2 expression was significantly up-regulated in PC9 cells transfected with pCDNA-KLF2 compared with control cells (Fig. 7A) . Meanwhile, MTT and colony formation assay results revealed that over-expression of KLF2 could impaired NSCLC cells proliferation (Fig. 7B) . Moreover, flow cytometry analysis indicated that increased KLF2 expression could induce NSCLC cells apoptosis (Fig. 7C) . Furthermore, to determine whether ANRIL regulate NSCLC cell proliferation via repressing KLF2 expression, rescue assays were performed. PC9 cells were co-transfected with si-ANRIL and si-KLF2, and this was shown to rescue the decreased expression of ANRIL induced by knockdown of KLF2 (Fig. 7D) . The results of MTT and colony formation assay results indicated that co-transfection could partially rescue si-ANRIL-impaired proliferation in PC cells (Fig. 7E) . These data indicate that ANRIL promotes NSCLC cell proliferation through the down-regulation of KLF2 expression.
Discussion
Recently, numerous pieces of evidence show that many lncRNAs are characterized and play important roles in cancer pathogenesis, suggesting that they could provide new insights into the biology of this disease. For example, increased lncRNA HOTTIP is associated with progression and predicts outcome in hepatocellular carcinoma patients by regulating HOXA13 expression (22) . However, the roles of lncRNAs in NSCLC are still not well documented, and one of these lncRNAs is metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), which is a highly conserved nuclear lncRNA and a predictive marker for metastasis development in lung cancer (23) . In our previous studies, we found that increased lncRNA HOTAIR promoted NSCLC cells invasion and metastasis via regulating HOXA5 expression, and lncRNA BANCR over-expression could impaired NSCLC cells proliferation and metastasis by affecting epithelial-mesenchymal transition (24, 25) .
In this study, we demonstrated that the expression of another lncRNA, ANRIL, is significantly up-regulated in NSCLC tissues. Specifically, increased ANRIL expression appears to be a significant, independent predictive value for NSCLC patients. Moreover, knockdown of ANRIL expression led to the significant inhibition of cell proliferation and the promotion of apoptosis both in vitro and in vivo. These findings suggest that ANRIL plays a direct role in the modulation of cell proliferation and NSCLC progression, and could be a useful novel prognostic or progression marker for NSCLC. As more and more lncRNAs are studied, many have been shown to function by binding with PRC2 and silencing downstream target genes that involved in multiple cancers including NSCLC (26, 27) .
ANRIL has been reported to involve in cancer cells proliferation by silencing p15 features such as inhibition of cell proliferation mediated by KRAS (32) (33) (34) . Moreover, there is evidence showed that EZH2 could silence KLF2 expression and block the tumor-suppressor features of KLF2, which is partly mediated by p21 (21) . Our results also showed lncRNA ANRIL take part in NSCLC cells proliferation by epigenetic silencing KLF2 and P21 transcription, and KLF2 inactivation further led to the decreased P21 expression. As more and more studies indicated that lncRNAs are often expressed in a spatial-or temporal-specific pattern, and more cell and tissue -specific pattern. Our results also showed that even in NSCLC cells, lncRNA ANRIL could regulate different target genes in different cell lines, which suggested that lncRNA, especially ANRIL, can influence the same cell biological function via regulating differnet target genes dependent on different cell lines.
To date, although only a small number of lncRNAs have been well characterized, they have been shown to regulate gene expression at various levels, including chromatin modification and post-transcriptional processing (35, 36) . Here, the possible other targets and mechanism that underlie such regulatory behaviors still remain to be fully understood despite our observation of ANRIL-induced NSCLC cell proliferation. In summary, the expression of ANRIL was significantly increased in NSCLC tissues, suggesting that its up-regulation may be a negative prognostic factor for NSCLC patients, indicative of poor survival rates, and a higher risk for cancer metastasis. We showed that ANRIL possibly 
